IndraLab
Statements
reach
"Also, worth investigating is whether USP19 inhibitors are promising drugs against tumors in general, or only some specific types of tumors, like liver cancers with p53 deletions/mutations that originate in a NAFLD background.In conclusion, this study shows that p53 deletion/mutation increases USP19, which in turn stabilizes SOAT1, increases cholesterol esterification and accelerates tumor progression (Figure 1)."